SCHEMBL7962956

SCHEMBL7962956

COc1cc(/C=N/NC(=O)C(OC)c2ccnc3ccccc23)cc(Br)c1OC

nearest known ligand 0.83

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.52
LMNA P02545 1/20 0.52
GAA P10253 1/20 0.46
HTT P42858 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7960319 0.94 MEN1 (0.51) MAPTLMNAGAAHTT
SCHEMBL7966405 0.91
SCHEMBL3223458 0.87 MEN1 (0.50) MAPTLMNAGAAHTT
SCHEMBL3223485 0.87 MEN1 (0.50) MAPTLMNAGAAHTT
SCHEMBL7951755 0.85
SCHEMBL7963662 0.79 MEN1 (0.47) MAPTLMNAHTT
SCHEMBL3204680 0.78 MEN1 (0.66) MAPTLMNA
SCHEMBL3204700 0.78 MEN1 (0.66) MAPTLMNA
SCHEMBL7961628 0.77
SCHEMBL7961565 0.76

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180118711-A1 PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS OMEROS CORPORATION 2018-05-03 US disclosed
US-9783521-B2 PDE10 inhibitors and related compositions and methods OMEROS CORPORATION (US) 2017-10-10 US disclosed
EP-2310016-B1 PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS OMEROS CORP (US) 2017-10-04 EP disclosed
US-20140038951-A1 PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS OMEROS CORPORATION (US) 2014-02-06 US disclosed
US-8377930-B2 PDE10 inhibitors and related compositions and methods OMEROS CORPORATION (US) 2013-02-19 US disclosed
US-8377930-B2 PDE10 inhibitors and related compositions and methods OMEROS CORPORATION (US) 2013-02-19 US disclosed
WO-2010017236-A1 PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS OMEROS CORPORATION (US) 2010-02-11 WO disclosed
US-20100035872-A1 PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS OMEROS CORPORATION (US) 2010-02-11 US disclosed
US-20100035872-A1 PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS OMEROS CORPORATION (US) 2010-02-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180118711-A1 PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS PDE10A, PDE9A, PDE7A MAPT 229/4885LMNA 3928/4885GAA 64/4885
US-20140038951-A1 PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS PDE10A, PDE9A, PDE7A MAPT 229/4885LMNA 3928/4885GAA 64/4885
US-20100035872-A1 PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS PDE10A, PDE9A, PDE7A MAPT 229/4885LMNA 3928/4885GAA 64/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.